Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQEC6Z)

Drug Name

Melanoma vaccine Drug Info

Synonyms

NA17.A2 peptides, Institut Curie; Vaccine (melanoma), Institut Curie; Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100); Melanoma vaccine (NA17.A2/tyrosinase/MART-1, gp100), Institut Curie

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 3	[1]

Cross-matching ID

TTD Drug ID: DMQEC6Z

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Approved Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Melanocytes lineage-specific antigen GP100 (PMEL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[3]
IMCgp100	DMUJ1WV	Cutaneous melanoma	2C30	Phase 2	[4]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[5]
Gp100:209-217(210M) peptide vaccine	DM38ARE	Melanoma	2C30	Phase 2	[6]
AE-08	DM7X2HK	Melanoma	2C30	Phase 1	[7]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting MART-1 melanoma antigen (MLANA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[3]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[9]
MKC-1106-MT	DMXKOW6	Melanoma	2C30	Phase 2	[10]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[8]
F-50040	DMMG6W5	Melanoma	2C30	Discontinued in Phase 1	[11]
------------------------------------------------------------------------------------

Drug(s) Targeting Tyrosinase (TYR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[12]
Monobenzone	DMVJS2K	Vitiligo	ED63.0	Approved	[12]
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[3]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[9]
MKC-1106-MT	DMXKOW6	Melanoma	2C30	Phase 2	[10]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[5]
PMID29130358-Compound-Figure11(3)	DMSME2B	N. A.	N. A.	Patented	[13]
Benzothiazole analog 1	DMHXFCQ	Albinism	EC23.2	Patented	[14]
Monoamine derivative 2	DMAZ6DI	Albinism	EC23.2	Patented	[14]
Benzimidazole derivative 3	DMY93WG	Albinism	EC23.2	Patented	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MART-1 melanoma antigen (MLANA)	TT362RB	MAR1_HUMAN	Not Available	[2]
Melanocytes lineage-specific antigen GP100 (PMEL)	TT8MK59	PMEL_HUMAN	Not Available	[2]
Tyrosinase (TYR)	TTULVH8	TYRO_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health.
2	National Cancer Institute Drug Dictionary (drug id 685201).
3	Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
4	Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
5	ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
6	National Cancer Institute Drug Dictionary (drug id 476335).
7	Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7.
8	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
9	An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
10	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
11	Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
12	Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
13	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
14	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.